Gilead Sciences, Inc. (NASDAQ:GILD) EVP James R. Meyers sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the sale, the executive vice president now owns 102,715 shares in the company, valued at $8,241,851.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Gilead Sciences, Inc. (GILD) traded down $0.23 during trading hours on Friday, reaching $80.94. 2,123,977 shares of the company’s stock were exchanged, compared to its average volume of 8,120,000. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The stock has a market capitalization of $105,560.00, a P/E ratio of 9.21, a P/E/G ratio of -1.77 and a beta of 1.13. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.75 earnings per share. research analysts anticipate that Gilead Sciences, Inc. will post 8.48 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.57%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.66%.
Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after acquiring an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after acquiring an additional 310,607 shares in the last quarter. FMR LLC increased its position in shares of Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after acquiring an additional 258,005 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after acquiring an additional 116,780 shares in the last quarter. 75.95% of the stock is owned by institutional investors.
Several equities analysts recently issued reports on GILD shares. BMO Capital Markets reissued a “hold” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Friday, October 20th. JPMorgan Chase & Co. set a $85.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Morgan Stanley reissued an “equal weight” rating and set a $83.00 price objective (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. Bank of America reduced their price objective on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 4th. Finally, Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective on the stock. in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eighteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $85.53.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.